Previous 10 | Next 10 |
Atreca Announces Licensing Agreement with Zymeworks Atreca Declares EphA2-Targeting ADC (ATRC-301) as Clinical Candidate Virtual R&D Day scheduled for today at 4:15 p.m. EDT SAN CARLOS, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: B...
The following slide deck was published by Zymeworks Inc. in conjunction with this event. For further details see: Zymeworks (ZYME) Presents at Rare Orphan Disease Virtual Summit - Slideshow
Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...
Lone Pine Capital’s 13F portfolio value decreased from $29.68B to $24.41B. The number of positions decreased from 39 to 29. They increased Amazon, RH, NetEase, Confluent, and Marqeta while reducing Block and dropping Moderna and Meta Platforms. The top three positions are A...
The following slide deck was published by Zymeworks Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Zymeworks Inc. 2021 Q4 - Results - Earnings Call Presentation
Start Time: 16:30 End Time: 17:19 Zymeworks Inc. (ZYME) Q4 2021 Earnings Conference Call February 24, 2022, 16:30 PM ET Company Participants Kenneth Galbraith - Chair and CEO Chris Astle - SVP and CFO Neil Klompas - COO Neil Josephson - CMO Jack Spinks - Manager of IR Conference Call Particip...
Zymeworks press release (NYSE:ZYME): Q4 Non-GAAP EPS of -$0.99 beats by $0.14. Revenue of $19.87M (+26.7% Y/Y) beats by $9.02M. For further details see: Zymeworks Non-GAAP EPS of -$0.99 beats by $0.14, revenue of $19.87M beats by $9.02M
Enrollment on track for both pivotal trials of zanidatamab in 1L gastroesophageal adenocarcinoma (GEA) and 2L biliary tract cancer (BTC). Announced submission of abstracts for upcoming clinical data for the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting. ...
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2021 financial results after market close on February 24 th , 2022. Following the announce...
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences. Guggenheim Oncology Conference 2022 . Zymeworks will participate virtually in ...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appoint...
VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that manage...